Revance Therapeutics

Description

• Revance, a Silicon Valley-based biotechnology company, is committed to the advancement of remarkable science. The company is developing a portfolio of products for aesthetic medicine and underserved therapeutic specialties, including dermatology, orthopedics and neurology. Revances science is based upon a proprietary TransMTS® peptide technology, which when combined with active drug molecules, may help address current unmet needs. Revances initial focus is on developing daxibotulinumtoxinA, the company's highly purified botulinum toxin, for a broad spectrum of aesthetic and therapeutic indications, including facial wrinkles and muscle movement disorders. The companys lead drug candidate, DaxibotulinumtoxinA for Injection (RT002), is currently in development for the treatment of glabellar lines, cervical dystonia and plantar fasciitis with the potential to be the first long-acting neuromodulator. The company holds worldwide rights for all indications of RT002 injectable and RT001 topical and the pharmaceutical uses of the TransMTS technology platform. More information on Revance may be found at www.revance.com.
• 

  Headquarters:7555 Gateway Boulevard , Newark, California, United States

  More
• 

  Phone Number: +1 510-742-3400

• 

  Website: https://www.revance.com

• 

  Employees:412

• 

  Revenue:$500M - 1B

• 

  Legal Name:Revance Therapeutics

• Revance Therapeutics's Social Media

  
• Is this data correct?

• |  NAICS Code: 541714  |

  Show More